BioXcel Therapeutics price target raised to $10 from $8 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BioXcel Therapeutics (BTAI) to $10 from $8 and keeps a Buy rating on the shares following the Q2 report. The firm cites “heightened enthusiasm” for BXCL501’s prospects for the target increase. The analyst views the SERENITY readout as low-risk and believes BioXcel could file for the expanded label of BXCL501 by the end of this year and may receive the label extension in the back half of 2026.